drugset / Trial / NCT06513364
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
Phase 2
Completed
40 enrolled
Beijing Wehand-Bio Pharmaceutical Co., Ltd
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the safety and efficacy of bi-weekly WH002(Paclitaxel Medium and Long Chain Fat Emulsion Injection,Cholesterol Bound) vs Paclitaxel both followed by bi-weekly Epirubicin and Cyclophosphamide as neoadjuvant treatment in women with HER2-negative breast cancer.
Timeline
- Start
- 2024-09-10
- Primary completion
- 2025-08-15
- Completion
- 2025-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | WH002 | Unknown | 260 mg/m2 | Intravenous |